Trial Profile
Eplerenone Treatment for Chronic Central Serous Chorioretinopathy in Hungarian Population
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Oct 2016
Price :
$35
*
At a glance
- Drugs Eplerenone (Primary)
- Indications Central serous chorioretinopathy
- Focus Adverse reactions; Therapeutic Use
- 15 Oct 2016 Status changed from active, no longer recruiting to completed.
- 23 Nov 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Jun 2016 as per ClinicalTrials.gov record.
- 23 Nov 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.